Volkswacht Bodensee - Obesity drug maker Novo Nordisk posts strong profit

Europe's most valuable company and the main driver of the Danish economy said it expected its 2024 full-year sales to be up by 23 to 27 percent from a year earlier, revising its earlier forecast of 22 to 28 percent.

It cited in a statement "the expectation of continued volume growth and capacity limitations at some manufacturing sites."

The group reported a 21-percent rise in net profit to 27.3 billion kroner ($3.94 billion) for the July-to-September period.

Sales jumped by 22 percent to 60 billion kroner, slightly under analysts' expectations.

Novo Nordisk is ramping up its manufacturing sites to keep up with surging demand for its new generation of effective weight-loss treatments using semaglutides.

Sales of Wegovy, which has been approved for use to treat obesity in Britain, Denmark, France, Germany, Norway and the United States, rose by 42 percent in the first nine months of the year.

Wegovy was also approved for use in China in June.

Sales of the company's other semiglutide bestseller, Ozempic -- an injectable anti-diabetic treatment which has become popular for its slimming properties -- soared by 54 percent in the same period.

Obesity has escalated into a global health crisis, affecting 900 million people worldwide, including over 40 percent of Americans and nearly a quarter of Europeans.

It is a risk factor for developing diabetes, some forms of cancer and complications from other diseases, such as Covid.

Difficult to treat, it is costly for healthcare systems and while its causes can be lifestyle-related, it can also be influenced by genetics.

Novo Nordisk has a hold on 74 percent of the market for weight-loss treatments.

The World Obesity Federation predicts that by 2035, over half of the world's population will be overweight or obese and the global economic impact could then exceed $4 trillion a year.

F.Wagner--VB